Jul. 3 at 9:15 AM
$SLNH TN-401 ASGCT data hit may 15. cohort 1 durable to 52 weeks, cohort 2 avg 67% PVC reduction. stock was ~
$1.10. market ignored it.
TN-201 MyPEAK-1 data hit june 3. all 6 patients reduced LVMI. KCCQ +36 in cohort 2. matched mavacamten on remodeling with one infusion vs a daily pill. ema PRIME. fda RDEP. stock was
$0.87 into the print, closed
$0.79. market ignored it.
now at
$0.79. warrants gone. cash discipline confirmed. six green sessions. higher lows.
napkin math on what’s already in the bag but not in the price:
• TN-201 cohort 2 clinical win:
$0.50-1.00
• TN-401 arrhythmia reductions (larger TAM than MYBPC3):
$0.50-1.50
• ema PRIME + fda RDEP regulatory de-risk:
$0.25-0.50
• pediatric MYBPC3 opportunity via MyClimb:
$0.50-1.00
• alnylam collab + platform optionality:
$0.25-0.50
• TN-301 phase 2 setup:
$0.25-0.50
sum:
$2.25 to
$5.00 of unpriced fundamental value sitting in a
$0.79 stock.
that’s not a price target. that’s a scan of what already exists that the market refused to look at for three months.
when the mandate gate breaks the re-rate doesn’t price against the next catalyst. it prices against the scoreboard.
holding. nfa
